Medivir To Acquire BioPhausia's Commercial Platform To Market HCV Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Medivir has a made a bid for BioPhausia in order to use the company as a commercial platform from which to market its hepatitis C drug, TMC435. Medivir sees the matter as urgent, as its drug is two years behind the competition.
You may also be interested in...
Sweden’s Medivir Prepares For Simeprevir And Profitability
Swedish hepatitis specialist Medivir aims to start Nordic marketing of its oral therapy simeprevir in 2014 and start anew as a profitable biotech with expansion prospects.
Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm
With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.
Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm
With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.